110 related articles for article (PubMed ID: 19122018)
1. Reduction in muscarinic M1-mediated hypercholinergic state and beneficial cognitive effects of muscarinic agonists in schizophrenia.
Pomara N
Am J Psychiatry; 2009 Jan; 166(1):111; author reply 111-3. PubMed ID: 19122018
[No Abstract] [Full Text] [Related]
2. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
Shekhar A; Potter WZ; Lightfoot J; Lienemann J; Dubé S; Mallinckrodt C; Bymaster FP; McKinzie DL; Felder CC
Am J Psychiatry; 2008 Aug; 165(8):1033-9. PubMed ID: 18593778
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice.
Woolley ML; Carter HJ; Gartlon JE; Watson JM; Dawson LA
Eur J Pharmacol; 2009 Jan; 603(1-3):147-9. PubMed ID: 19111716
[TBL] [Abstract][Full Text] [Related]
4. M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia.
Dean B
Neuropsychopharmacology; 2004 Aug; 29(8):1583-4; author reply 1585-6. PubMed ID: 15266348
[No Abstract] [Full Text] [Related]
5. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
Barak S; Weiner I
Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M
Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H
Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348
[TBL] [Abstract][Full Text] [Related]
7. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
Brannan SK; Sawchak S; Miller AC; Lieberman JA; Paul SM; Breier A
N Engl J Med; 2021 Feb; 384(8):717-726. PubMed ID: 33626254
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic properties of muscarinic drugs.
Janowsky DS; Davis JM
Am J Psychiatry; 2009 Jan; 166(1):110; author reply 110-1. PubMed ID: 19122017
[No Abstract] [Full Text] [Related]
9. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
Mirza NR; Peters D; Sparks RG
CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
[TBL] [Abstract][Full Text] [Related]
10. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation.
Medina A; Bodick N; Goldberger AL; Mac Mahon M; Lipsitz LA
Hypertension; 1997 Mar; 29(3):828-34. PubMed ID: 9052903
[TBL] [Abstract][Full Text] [Related]
11. Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions.
Bolbecker AR; Shekhar A
Handb Exp Pharmacol; 2012; (208):167-90. PubMed ID: 22222699
[TBL] [Abstract][Full Text] [Related]
12. Muscarinic acetylcholine receptors as CNS drug targets.
Langmead CJ; Watson J; Reavill C
Pharmacol Ther; 2008 Feb; 117(2):232-43. PubMed ID: 18082893
[TBL] [Abstract][Full Text] [Related]
13. Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.
Melancon BJ; Tarr JC; Panarese JD; Wood MR; Lindsley CW
Drug Discov Today; 2013 Dec; 18(23-24):1185-99. PubMed ID: 24051397
[TBL] [Abstract][Full Text] [Related]
14. Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials.
McArthur RA; Gray J; Schreiber R
Curr Opin Investig Drugs; 2010 Jul; 11(7):740-60. PubMed ID: 20571970
[TBL] [Abstract][Full Text] [Related]
15. 4-Phenylpyridin-2-one Derivatives: A Novel Class of Positive Allosteric Modulator of the M1 Muscarinic Acetylcholine Receptor.
Mistry SN; Jörg M; Lim H; Vinh NB; Sexton PM; Capuano B; Christopoulos A; Lane JR; Scammells PJ
J Med Chem; 2016 Jan; 59(1):388-409. PubMed ID: 26624844
[TBL] [Abstract][Full Text] [Related]
16. Muscarinic agonists for the treatment of cognition in schizophrenia.
Sellin AK; Shad M; Tamminga C
CNS Spectr; 2008 Nov; 13(11):985-96. PubMed ID: 19037177
[TBL] [Abstract][Full Text] [Related]
17. Long-term changes in the muscarinic M1 receptor induced by instantaneous formation of wash-resistant xanomeline-receptor complex.
De Lorme KC; Grant MK; Noetzel MJ; Polson SB; El-Fakahany EE
J Pharmacol Exp Ther; 2007 Dec; 323(3):868-76. PubMed ID: 17855477
[TBL] [Abstract][Full Text] [Related]
18. Classics in Chemical Neuroscience: Xanomeline.
Bender AM; Jones CK; Lindsley CW
ACS Chem Neurosci; 2017 Mar; 8(3):435-443. PubMed ID: 28141924
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists.
Heinrich JN; Butera JA; Carrick T; Kramer A; Kowal D; Lock T; Marquis KL; Pausch MH; Popiolek M; Sun SC; Tseng E; Uveges AJ; Mayer SC
Eur J Pharmacol; 2009 Mar; 605(1-3):53-6. PubMed ID: 19168056
[TBL] [Abstract][Full Text] [Related]
20. Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia.
Dean B
Curr Pharm Biotechnol; 2012 Jun; 13(8):1563-71. PubMed ID: 22283751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
